Core Points - Hofseth Biocare ASA ("HBC") has completed a private placement of new shares, as announced on 27 October 2025 [1] - Hofseth International AS was allocated 28,666,666 new shares at a subscription price of NOK 1.80 [1] Company Information - The private placement is part of HBC's strategy to raise capital through the issuance of new shares [1] - The completion of the private placement indicates HBC's ongoing efforts to strengthen its financial position [1] Regulatory Compliance - The information disclosed is subject to the Market Abuse Regulation article 19 requirements [2] - For further inquiries, contact details for the CEO of HBC are provided [2]

Core Viewpoint - Hofseth BioCare ASA ("HBC" or "the Company") is conducting a Subsequent Offering to raise gross proceeds of approximately NOK 30 million by issuing up to 16,666,666 new shares at a subscription price of NOK 1.80 per share, which is the same as the offer price in the recent Private Placement [2][3]. Subsequent Offering Details - The Subsequent Offering is conditional upon the approval of the Company's extraordinary general meeting (EGM) scheduled for around 20 November 2025, which will authorize the board of directors to issue shares [3][4]. - The offering is directed towards shareholders as of 24 October 2025, excluding those who participated in the Private Placement and those in jurisdictions where the offering would be unlawful [4]. - If Eligible Shareholders do not subscribe for all available shares, remaining shares may be allocated to Secondary Subscribers deemed strategically important by the Board [4][5]. - The subscription period will begin following the publication of an offering prospectus, and the Company reserves the right to cancel the offering if the shares trade at or below the offer price in significant volumes [5][6]. Important Dates and Information - Date of approval for the Subsequent Offering: On or about 20 November 2025 [4]. - Last day including right: 24 October 2025 [6]. - Ex-date: 27 October 2025 [6]. - Record date: 28 October 2025 [6]. - Maximum number of new shares to be issued: 16,666,666 [6]. - Subscription price per share: NOK 1.80 [6].

Core Viewpoint - Hofseth BioCare ASA ("HBC" or "the Company") is conducting a Subsequent Offering to raise gross proceeds of approximately NOK 30 million by issuing up to 16,666,666 new shares at a subscription price of NOK 1.80 per share, which is the same as the offer price in the recent Private Placement [2][3]. Subsequent Offering Details - The Subsequent Offering is conditional upon the approval of the Company's extraordinary general meeting (EGM) scheduled for around 20 November 2025, which will authorize the board of directors to issue shares [3][4]. - The offering is directed towards shareholders as of 24 October 2025, excluding those who participated in the Private Placement and those in jurisdictions where the offering would be unlawful [4]. - If Eligible Shareholders do not subscribe for all available shares, remaining shares may be allocated to Secondary Subscribers deemed strategically important by the board [4][5]. - The subscription period will begin following the publication of an offering prospectus, and the Company reserves the right to cancel the offering if the shares trade at or below the offer price in significant volumes [5][6]. Important Dates and Information - Date of approval for the Subsequent Offering: On or about 20 November 2025 [4]. - Last day including right: 24 October 2025 [6]. - Ex-date: 27 October 2025 [6]. - Record date: 28 October 2025 [6]. - Maximum number of new shares to be issued: 16,666,666 [6]. - Subscription price per share: NOK 1.80 [6].

Core Points - Hofseth BioCare ASA ("HBC") completed a private placement of new shares on 27 October 2025 [1] - Guy Urquhart subscribed for 55,444,444 new shares, increasing his holdings to 12.21% of the company [1] - Several shareholders experienced dilution of their holdings due to the private placement [1] Shareholder Holdings - Bonafide Wealth Management holds 66,023,125 shares, representing 14.54% of the ordinary shares [2] - Aqua-Spark holds 22,433,338 shares, corresponding to 4.94% of the ordinary shares [2] - Yokorei Co. Ltd. holds 40,951,333 shares, equating to 9.02% of the ordinary shares [2]

Core Points - Hofseth BioCare ASA ("HBC") completed a private placement of new shares on 27 October 2025 [1] - Guy Urquhart subscribed for 55,444,444 new shares, increasing his holdings to 12.21% of the company [1] - Several shareholders experienced dilution of their holdings due to the private placement [1] Shareholder Holdings - Bonafide Wealth Management holds 66,023,125 shares, representing 14.54% of the ordinary shares [2] - Aqua-Spark holds 22,433,338 shares, corresponding to 4.94% of the ordinary shares [2] - Yokorei Co. Ltd. holds 40,951,333 shares, equating to 9.02% of the ordinary shares [2]

Core Viewpoint - Hofseth BioCare ASA ("HBC") is conducting a private placement of new shares to raise capital for growth, balance sheet strengthening, and general corporate purposes, with a total size of approximately NOK 158 million from the issuance of 87,811,110 shares at NOK 1.80 each [2][3][4]. Group 1: Private Placement Details - The private placement consists of two tranches: Tranche 1 will raise NOK 106.5 million, while Tranche 2 will raise NOK 28.67 million, with the total expected proceeds being between NOK 155 million and NOK 181 million [2][4]. - The share capital increase will be executed through the issuance of 59,144,444 shares with a par value of NOK 0.01, and the first trading day for Tranche 1 shares is expected on or about 29 October 2025 [4][6]. - The completion of the private placement is contingent upon the registration of the share capital increase and the satisfaction of specific conditions related to the divestment of shares in AecorBio [5]. Group 2: Investor Participation - Major investors include Guy Urquhart, who subscribed for 55,444,444 shares for approximately NOK 100 million, and Hofseth International AS, which subscribed for 28,666,666 shares for about NOK 52 million [7]. - Shareholders representing 68.2% of the outstanding shares have committed to vote in favor of the share capital increase for Tranche 2 [6]. Group 3: Subsequent Offering - A subsequent offering of up to 16,666,666 new shares may be conducted, aimed at existing shareholders who did not participate in the private placement, potentially raising an additional NOK 30 million [9]. - The subsequent offering is subject to corporate approvals and market conditions, and any remaining shares may be allocated to strategic investors at the Board's discretion [9]. Group 4: Compliance and Structure - The Board of Directors has ensured that the private placement complies with Norwegian laws regarding equal treatment of shareholders and has structured the transaction to minimize completion risks compared to a rights issue [8]. - The proposed private placement is considered to be in the common interest of the company and its shareholders, despite deviations from shareholders' preferential rights [8].

Core Viewpoint - Hofseth BioCare ASA is launching a private placement between NOK 155 million and NOK 181 million and is partially divesting shares in its U.S. subsidiary AecorBio Inc, which is valued at approximately $36 million, reflecting a 20% premium compared to its last funding round [2][3][4] Company Summary - The company will divest 1,616,498 shares in AecorBio for about $5 million at a price of $3.0931 per share, resulting in HBC retaining approximately 52% ownership in AecorBio post-transaction [3][4] - AecorBio's lead peptide candidate, FT-002a, is in preclinical development for advanced prostate cancer, with an Investigational New Drug (IND) application planned for 2026 [4][6] - FT-002a aims to enhance the effectiveness of standard cancer therapies by directly modulating tumor iron metabolism, showing significant tumor volume reduction in preclinical studies [6][7] Industry Summary - The addressable market for resistant prostate cancer exceeds $2.5 billion annually, while the total ARPI market is over $10 billion and continues to grow [5] - Compelling preclinical data indicates that FT-002a can achieve up to an 80% reduction in tumor volume when combined with standard care, and up to 97% in hormone-sensitive advanced prostate cancer [6] - AecorBio is developing a multi-asset pipeline with additional preclinical programs in oncology and immunology, supported by a robust global intellectual property portfolio [7]

Core Viewpoint - Hofseth BioCare ASA ("HBC") is planning a private placement of new shares to raise between approximately NOK 155 million and NOK 181 million, aimed at capitalizing on the growing demand for salmon-derived nutrition and expanding its market presence [2][3]. Group 1: Private Placement Details - The private placement will consist of between 86,096,132 and 100,638,889 new shares at a fixed price of NOK 1.80 per share [2]. - Pre-commitments totaling approximately NOK 155 million have already been secured, with NOK 103.4 million in cash and NOK 52 million from debt conversion [2][7]. - The placement will be divided into two tranches, with Tranche 1 consisting of up to 68,555,556 shares and Tranche 2 up to 32,083,333 shares [8]. Group 2: Strategic Use of Proceeds - Proceeds will be allocated to expand the B2B ingredients unit and enhance customer adoption of nutraceutical offerings, particularly in high-growth regions like Asia and the US [3]. - Funds will support initiatives in metabolic health and healthy aging, following recent product successes and increased market interest [4]. - Investment will also focus on scaling the Brilliant Petcare brand, which is experiencing global growth in the premium pet nutrition segment [4]. Group 3: Partnerships and R&D - HBC aims to develop new concepts with global distributor partners and strengthen alliances with contract manufacturers, alongside general corporate purposes and marketing activities [5]. - The company will also allocate funds for further research and development to support its innovation pipeline [5]. Group 4: Divestment and Shareholding - In conjunction with the private placement, HBC will divest shares in AecorBio Inc. for approximately USD 5 million, reflecting a 20% valuation increase from the last funding round [6]. - Post-divestment, HBC will retain approximately 52% ownership in AecorBio [6]. Group 5: Regulatory and Application Process - The application period for the private placement starts on October 24, 2025, and is expected to close by October 27, 2025 [11]. - The completion of the private placement is subject to various conditions, including board resolutions and registration of share capital increases [12][13]. - An extraordinary general meeting (EGM) is expected to be convened around November 20, 2025, to approve the issuance of shares in Tranche 2 [15].

Core Insights - AecorBio Inc. has completed a $1.5 million equity financing round, valuing the company at $30 million, to advance its lead peptide candidate FT-002a for advanced prostate cancer [1] - FT-002a is a first-in-class peptide co-therapeutic that targets tumor iron metabolism, addressing a significant market opportunity in resistant prostate cancer, estimated at over $2.5 billion annually [2] - Preclinical data shows FT-002a can significantly reduce tumor volume, achieving an 80% reduction when combined with standard care and up to 97% in hormone-sensitive cases [3] - AecorBio is developing a multi-asset pipeline with additional preclinical programs in hormone-dependent oncology and immunology, supported by a robust intellectual property portfolio [4] - The CEO of AecorBio expressed strong investor confidence and highlighted the potential of FT-002a as a transformative therapy for treatment-resistant prostate cancer [5] Company Overview - AecorBio Inc. focuses on developing novel bioactive peptides for therapeutic applications in oncology, inflammatory, and autoimmune diseases, with FT-002a as the lead candidate [6] - The company is leveraging its proprietary peptide discovery platform to advance multiple drug candidates, supported by strong intellectual property and global academic collaborations [6] - Hofseth BioCare ASA retains approximately 67.5% ownership of AecorBio after the financing round, which will result in a NOK 8 million gain in financial income for Hofseth in Q3 2025 [5]

Core Insights - HBC has appointed Paul Bruhn as Head of New Business Development, bringing over 25 years of experience in healthcare and medical nutrition [1][2] - The company has developed a unique portfolio of bioactive ingredients derived from salmon, including OmeGo®, ProGo®, NT-II™, and PetGo®, which are scientifically backed and sustainable [3][4] - HBC emphasizes scientific evidence in its product development, leading to academic partnerships and the identification of unique health benefits [5][6] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources, upcycling side streams of the salmon industry [3][6] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [7] Product Portfolio - Key products include ProGo®, a mix of bioactive peptides and collagen; OmeGo®, a whole salmon oil; and CalGo® / NT-II®, a salmon bone powder for bone and joint health [4][5] - OmeGo® is noted for its full spectrum of Omega fatty acids, being 100% natural and clinically proven for various health benefits [3][5] Market Focus - HBC aims to address market needs for clinically backed nutrition sources, particularly in Asia, China, and the ANZ region [2][3] - The company is exploring potential therapeutics through its biotech-focused spin-off, HBC Immunology, targeting prostate and ovarian cancer, as well as asthma treatments [6]